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Abstract
Hepatoblastoma, the most common pediatric liver cancer, consists of epithelial mixed embryonal/fetal (EMEF)
and pure fetal histologic subtypes, with the latter exhibiting a more favorable prognosis. Few embryonal histology
markers that yield insight into the biologic basis for this prognostic discrepancy exist. CBP/P-300 interacting trans-
activator 1 (CITED1), a transcriptional co-activator, is expressed in the self-renewing nephron progenitor popula-
tion of the developing kidney and broadly in its malignant analog, Wilms tumor (WT). In this current study, CITED1
expression is detected in mouse embryonic liver initially on post-coitum day 10.5 (e10.5), begins to taper by e14.5,
and is undetectable in e18.5 and adult livers. CITED1 expression is detected in regenerating murine hepatocytes
following liver injury by partial hepatectomy and 3,5-diethoxycarbonyl-1,4-dihydrocollidine. Importantly, while
CITED1 is undetectable in normal human adult livers, 36 of 41 (87.8%) hepatoblastoma specimens express CITED1,
where it is enriched in EMEF specimens compared to specimens of pure fetal histology. CITED1 overexpression in
Hep293TT human hepatoblastoma cells induces cellular proliferation and upregulates the Wnt inhibitors Kringle con-
taining transmembrane protein 1 (KREMEN1) and CXXC finger protein 4 (CXXC4). CITED1 mRNA expression corre-
lates with expression of CXXC4 and KREMEN1 in clinical hepatoblastoma specimens. These data show that CITED1
is expressed during a defined time course of liver development and is no longer expressed in the adult liver but is
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Group; CXXC4, CXXC finger protein 4; DDC, 3,5-diethoxycarbonyl-1,4-dihydrocollidine; DKK1, Dickkopf-related protein 1; FBS, fetal bovine serum; KREMEN1, Kringle
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Address all correspondence to: Andrew J. Murphy, MD, Vanderbilt Children’s Hospital, 2200 Children’s Way, Suite 7102, Doctor’s Office Tower, Nashville, TN 37232-9780.
E-mail: andrew.j.murphy@vanderbilt.edu
1This work was supported by the Section of Surgical Sciences and the Ingram Cancer Center of the Vanderbilt Medical Center, by the National Cancer Institute (NCI) grant
5T32CA106183-06A1 (A.J.M.), and by NCI grant 4R00CA135695-03 (H.N.L.). The authors have no conflicts of interest to disclose.
2This article refers to supplementary materials, which are designated by Tables W1 to W3 and Figure W1 and are available online at www.neoplasia.com.
Received 14 June 2012; Revised 16 October 2012; Accepted 19 October 2012
Copyright © 2012 Neoplasia Press, Inc. All rights reserved 1522-8002/12/$25.00
DOI 10.1593/neo.12958
www.neoplasia.com
Volume 14 Number 12 December 2012 pp. 1153–1163 1153
upregulated in regenerating hepatocytes following liver injury. Moreover, as in WT, this embryonic marker is re-
expressed in hepatoblastoma and correlates with embryonal histology. These findings identify CITED1 as a novel
marker of hepatic progenitor cells that is re-expressed following liver injury and in embryonic liver tumors.
Neoplasia (2012) 14, 1153–1163
Introduction
Hepatoblastoma is the most common liver cancer of childhood and
is the third most common pediatric intra-abdominal malignancy
after neuroblastoma andWilms tumor (WT), respectively [1]. A variety
of hepatoblastoma histologic subtypes exist, with epithelial-type
hepatoblastomas being the most common [1]. Epithelial-type hepato-
blastomas are subdivided into either epithelial mixed embryonal/fetal
(EMEF) tumors, which contain both embryonal and fetal elements,
or pure fetal histology tumors, which contain disorganized cells re-
sembling fetal hepatocytes alone [1]. Pure fetal histology tumors have
a markedly improved prognosis relative to EMEF tumors; in fact, pure
fetal histology hepatoblastomas often are treated by surgical resection
alone and do not require the administration of cytotoxic chemotherapy,
a necessity in the treatment of all other hepatoblastomas [2].
Like other embryonal tumors, hepatoblastoma is thought to arise
from persistence of progenitor cells that escape terminal epithelial dif-
ferentiation during organogenesis and remain beyond birth. These
stem-like cells may undergo subsequent genetic insults that result in
neoplastic transformation in the embryonal tumorigenic sequence
[3]. In support of this progenitor cell hypothesis, hepatoblastomas
have been shown to share both a molecular phenotype and electron
micrographic features consistent with hepatic progenitor cells [4,5].
Moreover, components of the Wnt signaling pathway, which plays
a complex, but critical, role in promoting embryonic liver develop-
ment [6], are activated in a large proportion of hepatoblastomas.
In fact, hepatoblastoma has the highest reported frequency of activat-
ing β-catenin mutations of any cancer [7,8]. These findings indi-
cate that aberrant activation of a common signaling pathway required
for normal liver development may also play a role in the pathogenesis
of hepatoblastoma.
CBP/P-300 interacting transactivator 1 (CITED1) is a non-DNA
binding transcriptional co-activator that along with expression of an
additional transcription factor, SIX2, identifies the self-renewing por-
tion of nephron progenitor cells in the metanephric mesenchyme of
the developing kidney [9,10]. In the embryonic kidney, CITED1 is
expressed only in these progenitor cells during the period of nephro-
genesis and is downregulated as these cells undergo differentiation en
route to forming mature nephrons [9]. The functional role of CITED1
in kidney development is uncertain because CITED1 null mice do
not display altered nephrogenesis [9]. However, previous experiments
have shown that CITED1 inhibits Wnt4-dependent transcriptional
responses [11]. Because Wnt/β-catenin signaling in the metanephric
mesenchyme is a critical regulator of early nephron differentiation
[12], it is possible therefore that CITED1 modifies canonical Wnt/
β-catenin signaling in these nephron progenitor cells even though
genetic studies using CITED1 null mice indicate that its developmental
role is functionally redundant [9].
WT is an embryonal tumor that is the most common kidney cancer
of childhood and is thought to arise from arrested epithelial differentia-
tion of embryonic kidney nephron progenitor cells [13,14]. Like
hepatoblastoma, dysregulation of Wnt signaling and mutation of
β-catenin have been implicated in the pathogenesis of WT [15,16].
In this malignant context, we have previously shown that while
CITED1 expression is absent in the postnatal kidney, persistent expres-
sion of CITED1 is observed in a broad spectrum of WT [17,18].
Moreover, gain-of-function studies indicate that CITED1 enhances
cellular proliferation in a putative embryonal tumor cell line and over-
expression of a dominant-negative CITED1 construct perturbs embry-
onal tumor formation in a mouse xenograft model [17,19]. Taken
together, these data suggest that CITED1 may play a role in Wilms or
embryonal tumorigenesis and that these activities may relate to its ability
to block Wnt/β-catenin progenitor cell differentiation in this context.
On the basis of these findings, and given the roles of Wnt signaling
in normal liver development and hepatoblastoma, we hypothesized
that CITED1 misexpression might also play a role in the pathogenesis
of hepatoblastoma. In these studies, therefore, we have characterized
for the first time expression of CITED1 in hepatic development and
hepatoblastoma. We have shown that CITED1 is expressed in hepato-
blasts early in development. CITED1 expression is lost in the adult liver
but is strongly expressed in experimental and human hepatoblastoma
and also during hepatic regeneration following various forms of hepatic
injury. Although the functional role of CITED1 in liver development,
hepatoblastoma, and liver regeneration remains to be established, in
light of its role as a potential modulator of Wnt signaling and its asso-
ciation with embryonal tumorigenesis in the kidney, these studies
suggest that persistent CITED1 expression plays a role in regulating
and promoting hepatoblastoma.
Materials and Methods
CITED1LacZ Reporter Mouse
Development of the CITED1LacZ reporter mouse has been previ-
ously described [20]. For whole-mount staining for β-galactosidase
activity, embryos were isolated in cold phosphate-buffered saline (PBS)
and fixed in 0.2% glutaraldehyde in PBS with 2 mMMgCl2 and 5 mM
EGTA for 15 minutes. Fixed embryos were equilibrated in β-Gal wash
[0.1 M phosphate buffer (pH 7.3) containing 2 mM MgCl2, 5 mM
EGTA, 0.02% NP-40, and 0.01% Na deoxycholate] and stained over-
night at 37°C in β-Gal wash containing 1 mg/ml X-Gal and 5 mM
potassium ferrocyanate and ferricyanate. Embryos were visualized using
light microscopy. Timed pregnancies were counted with the morning
of vaginal plug appearance as day 0.5.
Hepatoblastoma and Liver Injury Specimens
Forty-one human hepatoblastoma specimens were included in this
analysis. A total of 19 paraffin-embedded and snap-frozen hepato-
blastoma tissue specimens were obtained from the Children’s Oncology
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Group (COG). Of these COG specimens, 11 were EMEF histology,
while 8 were of pure fetal histology. Clinical data were not available or
provided from the COG to correlate with patient outcomes. Twenty-
two formalin-fixed, paraffin-embedded specimens were available
from our institutional repository. Of these 22 institutional specimens,
17 were EMEF histology and 5 were of pure fetal histology. These
specimens were only available for immunohistochemistry.
Forty-three paraffin-embeddedmurine hepatoblastoma specimens, induced
chemically from N -nitrosodiethylamine, 2,3,7,8-tetrachlorodibenzo-p-
dioxin, were available for analysis [21]. To compare CITED1 reactivation
in other injury models, we subjected adult murine livers to two-thirds
partial hepatectomy or to exposure for 21 days of a diet containing
0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC), as previously
described [22]. DDC-fed mice were allowed 1 day of recovery following
DDC treatment and were sacrificed, and livers were subsequently fixed in
10% formalin and paraffin-embedded for immunohistochemical analy-
sis. Mice undergoing two-thirds partial hepatectomy were sacrificed at
3 and 7 days and livers were similarly prepared for immunohistochemical
analysis. All animal husbandry and experiments were conducted in
accordance with the standards of and prior approval from the Vanderbilt
University Medical Center Institutional Review Board and Institutional
Animal Care and Use Committee.
Immunohistochemistry and Immunofluorescence
All tissue samples were subjected to heat-induced antigen retrieval in
10 mM citrate buffer. These 5-μm sections were incubated in affinity-
purified rabbit anti-CITED1 (1:50 dilution; Lab Vision Corp, Fremont,
CA) antibody for 1 hour at room temperature. Goat anti-rabbit second-
ary antibody (1:200 dilution; Santa Cruz Biotechnology, Santa Cruz,
CA) was applied to tissues at room temperature for 45 minutes. Tissues
were visualized with either a Vectastain ABC Kit (Vector Laborato-
ries, Burlingame, CA) or DAKO Envision Kit (DAKOCytomation,
Carpinteria, CA). Immunohistochemistry was coded on an ordinal scale
of expression intensity (e.g., 0 = absent, 1 = weak, 2 = strong). Counts
of expression were compared overall, in the cytosol, and in the nucleus
by an observer blinded to the tissue samples. Proliferating cell nuclear
antigen (PCNA) immunostaining was performed similarly using a
1:1000 dilution of mouse anti-PCNA antibody (Santa Cruz).
For immunofluorescence experiments, tissues were similarly treated
and quenched using hydrogen peroxide. Mouse fetal heart, kidney, and
liver specimens were blocked using mouse-on-mouse block (Vector
Laboratories) with 0.5% hydrogen peroxide for 1 hour at room tem-
perature. Sections were then incubated in rabbit anti-CITED1 (1:100;
Lab Vision Corp) with mouse-on-mouse block, 10% goat serum, and
0.5% hydrogen peroxide in PBS overnight at 4°C. Anti-mouse HRP
(1:750 dilution; KPL, Gaithersburg, MD) was added for 40 minutes
at room temperature. For visualization of CITED1, anti-rabbit DyLight
549 (1:600 dilution; Jackson ImmunoResearch, West Grove, PA)
or fluorescein isothiocyanate–conjugated (1:100 dilution; Jackson
ImmunoResearch) antibodies were added for 2 hours at room temper-
ature. For ureteric bud staining, monoclonal mouse cytokeratin 8 -
(Troma-1 antibody, 1:50 dilution; Developmental Studies Hybridoma
Bank, Iowa City, IA) was used. TOPRO-3 or 4′,6-diamidino-2-
phenylindole, dilactate (DAPI) were used for nuclear staining.
Western Blot Analysis, β-Catenin Sequencing, and
Quantitative Real-time–Polymerase Chain Reaction
CITED1 Western blots were performed, as previously described
[18]. Immunoblots were performed using affinity-purified rabbit anti-
CITED1 (1:1000 dilution; Lab Vision Corp),M2 anti-FLAG antibody
(1:1000 dilution; Sigma Chemical Co, St Louis, MO), and mouse
anti–β-actin (1:5000 dilution; Sigma Chemical Co). Densitometry
was performed using Photoshop (Adobe, San Jose, CA). β-Catenin
Western blots were performed similarly using rabbit anti–β-catenin
antibody (1:1000 dilution; Cell Signaling Technology, Beverly, MA).
Results were normalized to β-actin. MCF7, a breast cancer cell line
known to express CITED1, was used for a CITED1-positive control.
COS cell lysate was used as a negative control. For developmental spec-
imens (fetal heart, kidneys, and liver), immunoprecipitation Western
blot analysis was performed as previously described [17].
To evaluate differences in gene transcription of CITED1 between
EMEF and pure fetal histology hepatoblastoma specimens, we iso-
lated and purified total RNA from snap-frozen tissues using RNAzol
(Tel-Test Inc, Friendswood, TX) and RNeasy Mini Kits (Qiagen,
Germantown, MD). Isolated RNA was quantified using a SpectraMax
M5 UV spectrophotometer (Molecular Devices, Sunnyvale, CA).
Reverse transcription (RT) of 3 μg of RNA was performed using
Superscript II reverse transcriptase (Invitrogen, Grand Island, NY)
and oligodT primers (Applied Biosystems, Foster City, CA) to syn-
thesize cDNA suitable for analysis by quantitative real-time–polymerase
chain reaction (qRT-PCR; Bio-Rad iCycler; Bio-Rad, Hercules, CA)
using iQ SYBR Green Super Mix (Bio-Rad). For Dickkopf-related
protein 1 (DKK1),Kringle containing transmembrane protein 1 (KREMEN1),
CXXC finger protein 4 (CXXC4), and PCNA, qRT-PCR was per-
formed using TaqMan probe–based gene expression analysis (Applied
Biosystems). Changes in mRNA expression were determined by com-
parison of sample cycle threshold values against a standard curve
generated using plasmid or positive control sample cDNA. Results
were normalized to the housekeeping gene GAPDH and compared
statistically. Primer sequences used for these studies are supplied in
Table W1.
To determine the mutational status of the CTNNB1 gene in the
hepatoblastoma samples provided by the COG, we amplified cDNA
with Taq polymerase using provided primer sequences flanking
exons 1 to 5 of the CTNNB1 gene (Table W1). Each reaction for
the primers covering exons 2 to 4 comprised 1× PCR buffer (Sigma-
Aldrich, St Louis, MO), 200 mM dNTP, 400 nM of each primer, and
0.05 units/ml Taq polymerase (Sigma-Aldrich); each reaction for the
primer set of exons 1 to 5 comprised 1× PCR buffer (Promega,
Madison, WI), 200 mM dNTP, 300 nM of each primer, 1% DMSO,
1mMMgCl2, and 2.5 units GoTaq Flexi DNA polymerase (Promega).
Cycling conditions were given as follows: 1) initial denaturation at
94°C for 3 minutes; 2) 42 cycles at 94°C for 40 seconds, 54°C for
40 seconds, and 72°C for 50 seconds; and 3) final elongation at 72°C
for 10 minutes. PCR products were gel purified using a QIAquick
Gel Extraction Kit (Qiagen, Valencia, CA) and subsequently directly
sequenced by GeneHunter Corporation (Nashville, TN). Gener-
ated sequences and chromatographs were compared to wild-type
CTNNB1 using the Basic Local Alignment Search Tool (BLAST;
NCBI, Bethesda, MD) to determine the mutational status of each
specimen. These methods could not determine the mutational status
of four tumors from the COG, leaving a total of 15 tumors analyzed
for CTNNB1 mutations. Base-pair references are made with respect
to sequence NM_001904 for CTNNB1.
To assess the effect of CITED1 overexpression on Wnt signaling in
hepatoblastoma, we isolated and quantified RNA from four consecutive
passages of both Hep293TT-pcDNA3 cells and Hep293TT-CITED1
cells using techniques described above. Reverse transcription (RT) was
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performed with 1 μg of RNA using the RT2 First Strand cDNA Syn-
thesis Kit (SABiosciences, Frederick,MD). TheRT2 Profiler PCR array
specific for the Wnt signaling pathway (PAHS-043A) was purchased
from SA Biosciences and used according to the manufacturer’s instruc-
tions. This array provides quantitative analysis of 84 Wnt pathway
components and target genes with expression normalized to a panel of
five housekeeping genes on a 96-well plate format.
CITED1 Misexpression Studies
CITED1 was misexpressed in the human hepatoblastoma cell line,
Hep293TT, using the Fugene HD cell transfection reagent (Promega)
[23]. An N-terminal FLAG-tagged CITED1 construct was inserted
into pCDNA3 vector (Invitrogen) containing a neomycin-resistance
cassette [24]. Subconfluent cells were transfected using 1 μg of plasmid
DNA. Seventy-two hours after transfection, 0.3 μg/ml G418 sulfate
(Sigma Chemical Co) was added to select for transfected cells. Result-
ing pooled colonies were isolated and passaged over a 6-week period
to foster generation of stable cell lines. Two stable cell lines were
generated: 1) empty-vector control cells, Hep293TT-pcDNA, and
2) a CITED1 overexpression cell line, Hep293TT-CITED1. Absence
or expression of CITED1 was verified by immunofluorescence and
Western blot.
In Vitro Studies: Proliferation and Soft Agar Assays
In vitro effects of CITED1 overexpression on cellular proliferation
were assayed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) incorporation using the CellTiter 96Non-Radioactive
Cell Proliferation Assay (Promega). The two aforementioned cell lines
were plated in starvation medium (ACL-4 media with 0.2% FBS) [25]
for 24 hours before experimentation. The cells were then harvested
and 5 × 104 cells were plated in 200 μl of ACL-4 media [25] with
0.2% FBS in four wells for each cell line at each time point tested.
MTT was added and quenched as per the manufacturer’s instructions.
Incorporation was assayed at 0, 24, 48, and 72 hours using spectro-
photometry. Absorbances were compared statistically. Results represent
four experimental repeats.
In vitro effects of CITED1 overexpression on anchorage-independent
growth were determined using soft agar assays. Twenty thousand cells
from each described cell line were plated in six separate wells of a six-
well plate in SeaPlaque GTG Agarose (Lonza, Rockland, ME) in ACL-
4 media (0.8% bottom agar and 0.4% top agar). Agars were covered in
200 μl of ACL-4 media and allowed to incubate for 3 weeks. Colony
counts and sizes were assayed using MTT staining and quantified using
a GelCount system (Oxford Optronix, Oxford, United Kingdom).
Results represent three experimental repeats.
Statistical Analysis
The incidence of strong [immunohistochemistry (IHC) score of 2
vs 0 or 1] CITED1 expression was compared between EMEF and pure
fetal histology specimens overall, in the cytosol, and in the nucleus
using Fisher exact test. The monotonic association between CITED1
and PCNA mRNA expression was estimated using the Spearman cor-
relation with 95% confidence intervals estimated by bootstrapping
(10,000 replicates). The Wilcoxon rank sum test was used to compare
the differences of normalized gene expression between the EMEF and
pure fetal histology hepatoblastomas for both qRT-PCR and Western
blot and to compare colony size and counts for the soft agar assay for
anchorage independent growth. Two-way analysis of variance was
used to compare proliferation profiles of Hep293TT-CITED1 to
Hep293TT-pcDNA3 cells over time using data generated by the
MTT proliferation assay, and this experiment was independently repli-
cated four times. A statistically significant (P < .0001) interaction between
treatment and time was detected among all four experiments. Con-
sequently, group comparisons were made at each time point in all four
experiments. Although we controlled the overall type I error at 0.05 for
all 16 time points (4 time points in each of four experiments) using the
method of Holm [26], only one experiment is presented. Statistical anal-
ysis from the RT2 Profiler PCR array specific for the Wnt signaling path-
way (PAHS-043A) was performed using the manufacturer’s statistical
software (SA Biosciences). All other analyses were performed using
R 2.13.1 (R Development Core Team, Vienna, Austria). Statistical tests
resulting in a P value less than .05 were considered statistically significant.
Results
Developmental Domains of CITED1 Expression
To determine the CITED1 expression domain across development,
we inspected whole-mount embryos at e11.5 from CITED1LacZ re-
porter mice. This analysis demonstrated β-galactosidase expression in
the heart, limbs, tail bud, and head mesenchyme (Figure 1) as pre-
viously described [27]. There is strong β-galactosidase staining in the
fetal liver at this stage of development (Figure 1). Expression in the
early metanephric kidney is obscured by the hind limb. To determine
more precisely when and where CITED1 is expressed during liver
development, we used immunohistochemistry to localize CITED1
protein using an affinity-purified rabbit polyclonal antibody that we
have previously shown is highly specific for CITED1 [9]. CITED1
was not detected at e9.5 in the murine liver diverticulum, an out-
pouching of the ventral foregut endoderm (Figure 2A). At e10.5,
CITED1 expression was detected in the liver bud (Figure 2B). Strong
CITED1 expression persisted during maturation of the liver bud from
Figure 1. (A) CITED1LacZ reporter mouse embryo at e11.5 gestation
reveals expression of CITED1 in the second branchial arch (white
arrow), fetal heart (white arrowhead), and fetal liver (black arrow-
heads). The hind limb obscures the metanephric kidney in this
projection. fl = forelimb; hl = hind limb.
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e11.5 to e13.5 (Figure 2, C–E ). CITED1 expression then tapered
between e14.5 and 16.5, at which point invading hematopoietic cells
were detected and the nuclear to cytosolic ratio of the CITED1-
positive hepatocytes began to decrease (Figure 2, F and G). CITED1
expression was not detected at e18.5, when the epithelial cells of the
fetal liver had a greatly decreased nuclear-to-cytoplasmic ratio typical of
maturing fetal hepatocytes (Figure 2H).
Consistent with immunohistochemical data, CITED1 was detected
in the fetal liver strongly by immunoprecipitationWestern blot at e13.5
but tapered by e16.5 and was undetectable in e19.5 livers (Figure 3A).
Interestingly, these data also show that CITED1 antibodies detect dis-
tinct mobility bands in embryonic liver versus heart and kidney. High
molecular weight bands detected in embryonic hearts at e13.5 collapse
to a single 27-kDa band when lysates are treated with alkaline phos-
phatase (data not shown). This is consistent with previous studies in-
dicating that CITED1 undergoes regulated phosphorylation events
[24]. The functional role of these phosphorylation events is unknown.
However, CITED1 immunolocalization studies in e12.5 mouse em-
bryos show cytosolic expression of CITED1 in the metanephric mes-
enchyme surrounding the ureteric bud tip epithelium (Figure 3B) and
in hepatoblasts of the liver bud (Figure 3D) but nuclear expression of
CITED1 in the trabeculae of the developing heart (Figure 3C). This
suggests that cardiac-specific CITED1 phosphorylation could play a
role in regulating CITED1 subcellular localization.
CITED1 Expression in an Experimental Murine Model
of Hepatoblastoma
Because of its expression in hepatic development, we next asked
whether CITED1 could also be detected in hepatoblastoma, a child-
hood malignancy that is characterized by cells with an embryonal and
abnormal progenitor-like phenotype. We started by testing for the pres-
ence of CITED1 in an experimental murine model of hepatoblastoma.
Chemically induced mouse hepatoblastomas were investigated for
CITED1 expression by immunohistochemistry [21]. CITED1 was
detected in 40 of 43 tumors (93% of experimental hepatoblastomas
analyzed; Figure 4, A and B). Unexpectedly, CITED1 was also detected
in adjacent areas of hepatic parenchymal injury and often coincided
with areas of steatosis (Figure 4, C and D). Because we noted intense
CITED1 staining in these areas of hepatic parenchymal injury, we
wanted also to determine whether CITED1 reactivation occurred in
other models of hepatic injury associated with liver regeneration. We
tested tissue sections from murine partial hepatectomy specimens and
murine livers treated with DDC, an inhibitor of heme biosynthesis that
leads to accumulation of porphyrin and induces oval cell proliferation,
Figure 2. (A) CITED1 is not detected by immunohistochemistry at
e9.5 of murine hepatic development, during the period of hepatic
specification as the liver diverticulum (ld) forms (hepatoblasts de-
laminate) from the ventral foregut endoderm. (B) By e10.5, CITED1
is strongly detected in the proliferating hepatic bud and not detected
in the adjacent septum transversum mesenchyme (stm). (C) At
e11.5, CITED1 is strongly detected in hepatoblasts, which form
hepatic cords (black arrows) following their invasion of the septum
transversummesenchyme. Sinusoids are also seen (white asterisks).
(D and E) CITED1 remains strongly detected at e12.5 and e13.5.
Hepatoblasts, black arrows; hematopoietic cells, white arrows.
(F and G) CITED1 expression begins to taper at e14.5 to e16.5, when
CITED1-negative invading hematopoietic cells can be seen (white
arrows) and the nuclear-to-cytoplasmic ratio of the hepatoblasts be-
gins to decrease (thin white arrow). (H) CITED1 expression is not de-
tected by e18.5, when hepatic cells have a lownuclear-to-cytoplasmic
ratio and have the appearance of fetal hepatocytes [original magnifi-
cation, ×400 (A–H)].
Figure 3. (A) Immunoprecipitation (IP)-Western blot for CITED1 in
e13.5, e16.5, e18.5, and e19.5 murine fetal kidney (K), heart (H),
and liver (L). Liver expression of CITED1 is strong at e13.5, but tapers
between e16.5 and 18.5, and is no longer detected by e19.5. Time
course of CITED1 expression in the kidney and heart is shown for
comparison. (B) Cytosolic detection of CITED1 is seen in the e12.5
murine fetal kidney capmesenchyme (pink) surrounding the ureteric
bud tip epithelium, which shows characteristic expression of cyto-
keratin 8 (green). (C) Nuclear detection of CITED1 in the trabeculae
of the developing heart at e12.5. (D) Cytosolic expression of CITED1
in hepatoblasts at e12.5 [original magnification ×400 (B and D)].
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the proposed progenitor cell of the adult liver [22]. CITED1 reactivation
was detected in all cases, particularly surrounding portal triads in both
the partial hepatectomy and DDC models and surrounding both portal
triads and central veins in the partial hepatectomy model (Figure 4,
F and H).
Immunohistochemical Detection of CITED1 in
Human Hepatoblastoma
We next tested the presence of CITED1 in human hepatoblastoma
specimens. CITED1 was detected by immunohistochemistry in 36 of
41 (87.8%) specimens analyzed. Of note, the six specimens in which
CITED1 was not detected were all of pure fetal histology (Figure 5A).
CITED1 was observed strongly in embryonal areas of EMEF histology
hepatoblastomas (Figure 5, B–F). Overall, CITED1 was strongly ex-
pressed in 23 of 28 (82.1%) EMEF histology tumors compared to 1 of
13 pure fetal histology tumors (Fisher exact test; P < .0001). Nuclear
expression was strong in 11 (39.3%) of 28 EMEF histology samples,
whereas none of the pure fetal samples expressed nuclear CITED1
strongly (Fisher exact test; P < .009). Strong cytosolic expression of
CITED1 was expressed in 23 of 28 EMEF histology tumors compared
to 1 of 13 pure fetal histology tumors (Fisher exact test; P < .0001).
Often, areas of abrupt transition in CITED1 expression correlated
with the juxtaposition of embryonal and fetal histology in EMEF
Figure 4. (A and B) Detection of CITED1 in theN -nitrosodiethylamine,
2,3,7,8-tetrachlorodibenzo-p-dioxinmurinemodel of hepatoblastoma.
(CandD)CITED1-positiveareasof injured liver in theN -nitrosodiethylamine,
2,3,7,8-tetrachlorodibenzo-p-dioxinmurinemodel often coincidedwith
areas of hepatic steatosis (black arrow); original magnification, ×200.
(E) Normal, uninjured murine liver is negative for CITED1. (F) Nuclear
enrichment of CITED1 is observed by immunohistochemistry at 7 days
post-murine partial hepatectomy surrounding portal triads (pt) and
central veins (cv). (G) IgG control of DDC induced murine liver injury.
Note porphyrin accumulation (black arrows) characteristic of this
injury model. (H) CITED1 is detected in DDC injured mouse liver
21 days post-exposure, and expression is enriched surrounding
portal triads but not clearly central veins; original magnification,
×200 (A–H).
Figure 5. (A) Pure fetal histology hepatoblastomas often did not
show immunohistochemical detection of CITED1; original magnifica-
tion,×200. (B) In EMEF tumors, CITED1 expressionwasmore greatly
detected in embryonal (em) elements, when compared to fetal (fe)
elements; original magnification, ×200. (C) High power representa-
tion of transition between embryonal and fetal elements; original
magnification, ×400. (D) An EMEF histology hepatoblastoma exhibit-
ingCITED1expression in embryonal and fetal elements; originalmag-
nification, ×200. (E and F) CITED1 is richly detected in the embryonal
elements of EMEF histology tumors [original magnification, ×200
(E); ×400 (F)]. (G) Immunofluorescence shows dysregulated nuclear
(single white arrows) and cytosolic (double white arrows) subcellular
localization of CITED1 in hepatoblastoma. (H) Merged image of
CITED1 (green) and TOPRO3 nuclear stain (red) [original magnifica-
tion, ×400 (G and H)].
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histology tumors (Figure 5, B and C ). By immunofluorescence, we
observed both cytosolic and nuclear expression of CITED1 in hepato-
blastoma (Figure 5, G and H).
Quantification of CITED1 Expression in Pure Fetal and
EMEF Histology Hepatoblastomas
To test the hypothesis that CITED1 expression is greater in more
undifferentiated tumors, we performed qRT-PCR and Western blot
analysis on hepatoblastomas provided by the COG. While expression
of CITED1 mRNA was similar between EMEF and pure fetal histol-
ogy tumors (Figure 6A), we did detect a marginal increase in CITED1
expression by Western blot for EMEF histology specimens (Wilcoxon
rank sum test; P = .085; Figure 6, B and C ).
Functional Significance of CITED1 Overexpression in
Human Hepatoblastoma Cells
To investigate the possible function of CITED1 in hepatoblastoma
pathogenesis, we established stable Hep293TT human hepatoblastoma
cell lines expressing either epitope-tagged CITED1 or empty vector
control. The presence and absence of both CITED1 and FLAG expres-
sion in these experimental cell lines were confirmed by Western blot
(see Figure 8A) and immunofluorescence confirmed expression in all
of the selected cells (data not shown).
CITED1 overexpression resulted in a statistically significant in-
crease in cell numbers as determined by MTT proliferation assay by
48 and 72 hours after assay initiation in all four experiments; in three
of four experiments, this difference was also statistically significant at
24 hours (Figure 7A; Holm-Bonferroni method; P < .05 all time
points). Decreased MTT detection in the control cell line initially in-
dicates potential death of control cells in serum-starved conditions.
CITED1 overexpression did not, however, significantly affect colony
size or colony count when compared to Hep293TT-pcDNA3 empty
vector control cells by soft agar assay for anchorage-independent growth
(Wilcoxon rank sum test; P = .083 colony size; P = .563 colony count).
To validate this association between CITED1 overexpression and in-
creased hepatoblastoma cellular proliferation, we tested for a correlation
between increasing CITED1 and PCNA mRNA expression in human
hepatoblastoma patient specimens. In the 19 hepatoblastomas provided
by the COG, we detected a statistically significant positive correlation
between increasing CITED1 and PCNA mRNA expression (Spearman
correlation coefficient = 0.554; 95% confidence interval (CI) = 0.061–
0.858; P = .015; Figure 7B). CITED1 and PCNA expression local-
ized to similar cellular expression domains by immunohistochemical
staining of serial hepatoblastoma tissue sections (Figure 7, C–F).
Given the potential role of CITED1 as an inhibitor of theWnt path-
way from previous studies and the importance of dysregulated Wnt
signaling in hepatoblastoma pathogenesis [28], we tested whether
CITED1 overexpression altered Wnt signaling in human hepato-
blastoma cells. Using the RT2 Profiler PCR array specific for the
Wnt signaling pathway (SA Biosciences), four biologic replicates (pas-
sages) of Hep293TT-CITED1 cells showed significant up-regulation
of the Wnt inhibitors KREMEN1 and CXXC4 (P = .034 and .043, re-
spectively) and also the Wnt effector DVL2 (P = .042) when compared
to Hep293TT-pcDNA3 empty vector control cells (Figure 8B). Com-
plete array data are provided (Tables W2a–W2g). To validate these
findings in the context of CITED1 overexpression in human hepato-
blastomas in vivo, we tested for a correlation between CITED1 mRNA
expression and that of KREMEN1 and CXXC4 in human hepato-
blastoma patient specimens. In the 19 hepatoblastomas provided by
the COG, we detected a statistically significant positive correlation be-
tween increasing CITED1 and CXXC4 mRNA expression (Spearman
Figure 6. (A) While the highest CITED1-expressing tumors were EMEF histology, there was no difference in mean CITED1 expression
detected by qRT-PCR normalized to β-actin (P = NS). (B) CITED1 expression was marginally higher in EMEF histology specimens by
Western blot densitometry normalized to β-actin (P = .085). (C) Example of Western blot demonstrating increased CITED1 expression
in hepatoblastoma specimens of EMEF histology. Positive control is MCF7 cell lysate, a breast cancer cell line that is known to express
high levels of CITED1.
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correlation coefficient = 0.521; 95% CI = 0.061–0.787 P = .024;
Figure 7C ). Likewise, we detected a significant positive correlation
between increasing CITED1 and KREMEN1 mRNA expression
(Spearman correlation coefficient = 0.553; 95% CI = 0.143–0.807
P = .016; Figure 7D). Because KREMEN1 is the DKK1 receptor,
we also tested whether an association was present between CITED1
and DKK1, which specifically has been shown to become dysregulated
in hepatoblastoma [29]. Although no statistically significant correla-
tion was detected between CITED1 and DKK1 expression in these
clinical specimens (Spearman correlation coefficient = 0.23; P = .342;
Figure 7E ), we did note a statistically significant increase in DKK1
expression in mixed-epithelial histology relative to pure fetal histology
specimens (Wilcoxon rank sum test; P = .003; Figure 7F).
CITED1 Expression and CTNNB1 Mutational Status
Given the detected correlations between CITED1 expression and
components of the Wnt pathway, we determined the mutational
status of CTNNB1 in hepatoblastoma specimens provided by the
COG by sequencing exons 1 to 5 from cDNA samples reverse tran-
scribed from isolated RNA (Table W3). Ten of 15 (66.7%) hepato-
blastoma specimens were found to have a CTNNB1 mutation. Seven
of 10 (70%) CTNNB1mutant hepatoblastoma specimens were EMEF
histology, whereas 3 of 10 (30%) were of pure fetal histology (P =
.957). Mean CITED1 expression by Western blot densitometry nor-
malized to β-actin was not statistically different between CTNNB1
mutant and wild-type groups (P = .817). However, by Western blot
densitometry normalized to β-actin, there was a statistically significant
correlation between CITED1 and β-catenin expression (Spearman
correlation coefficient = 0.52; P = .033). CITED1 and β-catenin also
had similar regions of expression within a given tumor by immuno-
histochemical staining of serial tumor sections (Figure W1).
Discussion
Our data show that CITED1 is expressed in developing hepatoblasts
during maturation of the liver bud and tapers off as these cells differen-
tiate into hepatocytes. Analogous to this embryonic context, CITED1
expression appeared greatest in the undifferentiated embryonal tumor
elements of mixed-epithelial hepatoblastoma. Prognostically more
favorable pure fetal histology tumors, and even the more differentiated
fetal areas of EMEF histology tumors, showed lower expression of
CITED1. In addition, as previously described in renal progenitor cells
andWT [17], the subcellular localization of CITED1 is dysregulated in
hepatoblastoma when compared to its predominantly cytosolic local-
ization in hepatic development. Functionally, CITED1 overexpres-
sion in human hepatoblastoma cells increases cellular proliferation
but does not affect tumorigenesis in vitro, as measured by soft agar
assay of anchorage-independent growth. Proliferation of cells in which
CITED1 was overexpressed was often accompanied by apparent
cell death in the control group cells, potentially indicating a survival
advantage conferred by CITED1 overexpression in low-serum con-
ditions consistent with cell stress. The association between CITED1
activity and cellular proliferation was also apparent in hepatoblastoma
clinical specimens. CITED1 was further detected in a nitrosamine and
aromatic hydrocarbon–induced murine model of hepatoblastoma;
Figure 7. (A) An MTT cell proliferation assay in ACL-4 media with
0.2% FBS demonstrates a significant increase in cellular prolifera-
tion at 24, 48, and 72 hours with CITED1 overexpression (method
of Holm-Bonferroni; P< .05). (B) qRT-PCR of human hepatoblastoma
specimens reveals a positive correlation between expression of
CITED1 and the proliferative marker PCNA (Spearman correlation
coefficient= 0.554;P= .015). (C andD) Serial hepatoblastoma tissue
sections immunostained for (C) CITED1 and (D) PCNA demonstrate
similar patterns of expression within a given tumor, supporting the
correlation between CITED1 expression and cellular proliferation
(original magnification, ×200). (E and F) Additional serial sections
stained for (E) CITED1 and (F) PCNA (original magnification, ×100).
Figure 8. (A) Western blot demonstrates overexpression of CITED1 and detection of epitope-tagged CITED1 (FLAG) in Hep293TT human
hepatoblastoma cells transfected with FLAG-tagged wild-type CITED1 (Hep293TT-CITED1) compared to empty vector control plasmid
(Hep293TT-pcDNA3). Positive control is MCF7 breast cancer cell line and negative control is COS cell line. (B) qRT-PCR using a Wnt-PCR
array revealed a statistically significant increase in fold change of the Wnt inhibitors CXXC4 (log2 fold change = 2.88) and KREMEN1 (log2
fold change = 1.60) and also the Wnt effector DVL2 (log2 fold change = 1.21) after CITED1 overexpression. (C and D) qRT-PCR of human
hepatoblastoma specimens reveals a correlation between expression of (C) CITED1 and the Wnt inhibitor CXXC4 (Spearman correlation
coefficient = 0.521; P = .024) and (D) CITED1 and the Wnt inhibitor KREMEN1 (Spearman correlation coefficient 0.553; P = .016).
(E) No correlation was detected in clinical hepatoblastoma specimens between expression of CITED1 and the KREMEN1 ligand DKK1
(Spearman correlation coefficient = 0.23; P = .342). (F) However, DKK1 was found to be expressed greater in EMEF histology than pure
fetal histology hepatoblastoma specimens (P = .003).
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however, we also saw reactivation of CITED1 expression in surround-
ing areas of hepatic parenchymal injury, providing additional evidence
for a possible reactivation of embryonal transcriptional programs in
liver injury and regeneration. Reactivation of CITED1 expression asso-
ciated with hepatic injury and regeneration was confirmed after murine
partial hepatectomy and DDC treatment, which both induce oval cell
proliferation, a key marker of hepatic regeneration. Taken together, we
speculate that CITED1 expression in hepatoblastomas either persists
postnatally or becomes reactivated in the neoplastic transformation
from progenitor to cancer cell, as inferred from the chemically induced
murine model.
CITED1 expression has not been previously reported in human
or murine liver development, although the related family member,
CITED2, is critical for hepatic development through its interactions
with hepatocyte nuclear factor-alpha 4 (HNF-α 4), a required tran-
scription factor for epithelial differentiation in the developing liver
[30]. Although expression of CITED1, from our study, appears to
adhere to a similar developmental time frame to that reported for
CITED2,CITED1 null mice do not exhibit any overt hepatic morpho-
logic or histologic abnormalities (data not shown), implying functional
redundancy of signaling similar to what has been observed in nephro-
genesis [9].While CITED1 null mice do exhibit decreased hepatic mass
relative to controls, this is caused by asymmetric intrauterine growth
retardation secondary to placental insufficiency [31].
The Wnt signaling pathway has been implicated in maintaining the
critical, coordinated balance between differentiation and proliferation
in multiple developmental contexts, particularly in the developing liver
[6]. Wnt/β-catenin plays a biphasic role in hepatic development, with
suppression of signaling until after the period of hepatic specification,
followed by increased signaling driving the proliferation of hepatoblasts
[6]. Specifically, coordinated control of Wnt signaling has been linked
to the transcriptional co-activators, CBP and P300, which are the prin-
cipal proteins with which CITED1 interacts [32,33]. CITED1 may
therefore participate as a co-regulator in the modulation and balance
of CBP/β-catenin–mediated transcription critical for stem/progenitor
cell maintenance and P300/β-catenin–mediated transcription important
in the initiation of cellular differentiation.
Disruption of balanced Wnt signaling is critical in hepatoblastoma
pathogenesis, with between 50% and 90% of hepatoblastomas harbor-
ing β-catenin mutations [7,8]. Despite activated and pro-proliferative
Wnt signaling being a dominant feature in hepatoblastoma, eleva-
tion of multiple Wnt antagonists including TrCP, Nkd-1, AXIN2,
and DKK1 have been previously reported, possibly signifying a non-
functional negative feedback loop [29,34]. Because CITED1 is a
potential repressor of the Wnt pathway [11], we evaluated the effects
in vitro of overexpressing CITED1 on Wnt pathway genes. In these
studies, we found that CITED1 overexpression was associated with
up-regulation of two key components of Wnt signaling inhibition:
KREMEN1 andCXXC4. We validated these findings in clinical hepato-
blastoma specimens, which revealed thatCITED1mRNA expression cor-
related positively with the Wnt components, KREMEN1 and CXXC4,
independent of histologic subtype. DKK1 expression (another inhibi-
tor of Wnt signaling) did not correlate with CITED1 mRNA ex-
pression but increased in association with mixed (more embryonal)
histology. These findings implicate CITED1 as a modulator of Wnt
signaling in hepatoblastoma and possibly also liver development. The
seemingly paradoxical role of CITED1-promoted increased cellular
proliferation and Wnt inhibition in the malignant context implies,
analogously, a persistent developmental role, which may be specific
to stem-like cells, whether embryonic progenitors or a cancer stem cell.
Speculatively, CITED1maymodulateWnt signaling to simultaneously
promote or inhibit differentiation and maintenance/proliferation of
the progenitor cell pool in a developing organ.
From these studies, the detection of CITED1 in hepatoblastoma
appears to be linked to undifferentiated, embryonal tumor elements.
We detected increased CITED1 by immunohistochemistry in EMEF
histology hepatoblastomas containing both embryonal and fetal ele-
ments when compared to more differentiated, pure fetal histology
hepatoblastomas. This observation was not statistically supported by
qRT-PCR, whereas a marginally significant increase was detected by
Western blot. CITED1 expression appeared to inversely correlate with
tumor differentiation, a finding that may have prognostic importance
given that pure fetal histology hepatoblastomas exhibit favorable be-
havior and are able to be treated by surgical resection alone without
chemotherapy. Furthermore, we detected an association between the
Wnt inhibitor DKK1mRNA expression and mixed-epithelial histology
tumors. Taken together, these results suggest that CITED1 may confer
a survival advantage to the more primitive cellular components of
hepatoblastoma by enhancing proliferation independent of oncogenic
behavior and may further promote maintenance of stem-like prop-
erties in this embryonal malignancy by inhibiting Wnt-dependent
mechanisms of cellular differentiation.
The role of CITED1 as a marker of the self-renewing stem cell pop-
ulation in kidney development and the promotion of cellular prolif-
eration by CITED1 overexpression in human hepatoblastoma cells in
the current study perhaps suggest a role for CITED1 in cancer cell
self-renewal. Its role as a marker of hepatoblasts before epithelial tran-
sition and its link to undifferentiated tumor elements may implicate
CITED1 in a network of gatekeepers that inhibit developmental pro-
genitor or embryonal tumor cell differentiation. Therefore, CITED1
and its associated pathways may provide fertile ground for potential
pathway-targeted therapies that abrogate cancer cell self-renewal or
promote terminal differentiation of embryonal tumors.
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Table W1. Primer Sequences.
Gene Primer Sequence or Catalog Number (for TaqMan Assays)
qRT-PCR primer sequences
CITED1 Forward primer, 5′-AGGATGCCAACCAAGAGATG-3′
Reverse primer, 5′-TGGTTCCATTTGAGGCTACC-3′
CXXC4 Forward primer, 5′-CAACCCAGCCAAGAAGAAGA-3′
Reverse primer, 5′-AGATCTGGTGTCCCGTTTTG-3′
DKK1 Forward primer, 5′-TCCGAGGAGAAATTGAGGAA-3′
Reverse primer, 5′-CCACAGTAACAACGCTGGAA-3′
KREMEN1* Hs00230750_m1 (spans exons 2–3 junction)
PCNA* Hs00427214_g1 (spans exons 3–4 junction)
GAPDH* Hs99999905_m1 (spans exons 3–4 junction)
cDNA sequencing primers for detection of CTNNB1 mutations
CTNNB1 Forward primer (exons 2–4), 5′-AAAATCCAGCGTGGACAATGG-3′
Reverse primer (exons 2–4), 5′-TGTGGCAAGTTCTGCATCATC-3′
Forward primer (exons 1–5), 5′-GGAGGAAGGTCTGAGGAGCAG-3′
Reverse primer (exons 1–5), 5′-CGATGATGGGAAGGTTATGC-3′
*TaqMan probe–based gene expression analysis assays from Applied Biosystems. Sequences are
proprietary, but exon-exon boundaries to which primers and probe are designed are listed.
Table W2a. Gene List for Wnt Pathway RT2 PCR Array.
Position Unigene Refseq Symbol Description
A01 Hs.515053 NM_001130 AES Amino-terminal enhancer of split
A02 Hs.158932 NM_000038 APC Adenomatous polyposis coli
A03 Hs.592082 NM_003502 AXIN1 Axin 1
A04 Hs.415209 NM_004326 BCL9 B cell CLL/lymphoma 9
A05 Hs.643802 NM_033637 BTRC β-Transducin repeat containing
A06 Hs.17631 NM_003468 FZD5 Frizzled family receptor 5
A07 Hs.523852 NM_053056 CCND1 Cyclin D1
A08 Hs.376071 NM_001759 CCND2 Cyclin D2
A09 Hs.534307 NM_001760 CCND3 Cyclin D3
A10 Hs.529862 NM_001892 CSNK1A1 Casein kinase 1, α1
A11 Hs.631725 NM_001893 CSNK1D Casein kinase 1, Δ
A12 Hs.646508 NM_022048 CSNK1G1 Casein kinase 1, γ1
B01 Hs.644056 NM_001895 CSNK2A1 Casein kinase 2, α1 polypeptide
B02 Hs.208597 NM_001328 CTBP1 C-terminal binding protein 1
B03 Hs.501345 NM_022802 CTBP2 C-terminal binding protein 2
B04 Hs.476018 NM_001904 CTNNB1 Catenin (cadherin-associated protein), β1, 88 kDa
B05 Hs.463759 NM_020248 CTNNBIP1 Catenin, β interacting protein 1
B06 Hs.12248 NM_025212 CXXC4 CXXC4
B07 Hs.654934 NM_014992 DAAM1 Dishevelled associated activator of morphogenesis 1
B08 Hs.655626 NM_033425 DIXDC1 DIX domain containing 1
B09 Hs.40499 NM_012242 DKK1 Dickkopf homolog 1 (Xenopus laevis)
B10 Hs.74375 NM_004421 DVL1 Dishevelled, dsh homolog 1 (Drosophila)
B11 Hs.118640 NM_004422 DVL2 Dishevelled, dsh homolog 2 (Drosophila)
B12 Hs.517517 NM_001429 EP300 E1A binding protein p300
C01 Hs.484138 NM_012300 FBXW11 F-box and WD repeat domain containing 11
C02 Hs.494985 NM_012164 FBXW2 F-box and WD repeat domain containing 2
C03 Hs.1755 NM_002007 FGF4 Fibroblast growth factor 4
C04 Hs.283565 NM_005438 FOSL1 FOS-like antigen 1
C05 Hs.663679 NM_003593 FOXN1 Forkhead box N1
C06 Hs.126057 NM_005479 FRAT1 Frequently rearranged in advanced T cell lymphomas
C07 Hs.128453 NM_001463 FRZB Frizzled-related protein
C08 Hs.36975 NM_000510 FSHB Follicle stimulating hormone, β polypeptide
C09 Hs.94234 NM_003505 FZD1 Frizzled family receptor 1
C10 Hs.142912 NM_001466 FZD2 Frizzled family receptor 2
C11 Hs.40735 NM_017412 FZD3 Frizzled family receptor 3
C12 Hs.19545 NM_012193 FZD4 Frizzled family receptor 4
D01 Hs.591863 NM_003506 FZD6 Frizzled family receptor 6
D02 Hs.173859 NM_003507 FZD7 Frizzled family receptor 7
D03 Hs.302634 NM_031866 FZD8 Frizzled family receptor 8
D04 Hs.466828 NM_019884 GSK3A Glycogen synthase kinase 3α
D05 Hs.445733 NM_002093 GSK3B Glycogen synthase kinase 3β
D06 Hs.714791 NM_002228 JUN Jun proto-oncogene
D07 Hs.229335 NM_001039570 KREMEN1 Kringle containing transmembrane protein 1
D08 Hs.555947 NM_016269 LEF1 Lymphoid enhancer-binding factor 1
D09 Hs.6347 NM_002335 LRP5 Low density lipoprotein receptor-related protein 5
D10 Hs.584775 NM_002336 LRP6 Low density lipoprotein receptor-related protein 6
D11 Hs.202453 NM_002467 MYC V-myc myelocytomatosis viral oncogene homolog (avian)
D12 Hs.592059 NM_033119 NKD1 Naked cuticle homolog 1 (Drosophila)
Table W2a. (continued )
Position Unigene Refseq Symbol Description
E01 Hs.208759 NM_016231 NLK Nemo-like kinase
E02 Hs.643588 NM_000325 PITX2 Paired-like homeodomain 2
E03 Hs.386453 NM_022825 PORCN Porcupine homolog (Drosophila)
E04 Hs.483408 NM_002715 PPP2CA Protein phosphatase 2, catalytic subunit, α isozyme
E05 Hs.467192 NM_014225 PPP2R1A Protein phosphatase 2, regulatory subunit A, α
E06 Hs.256587 NM_015617 PYGO1 Pygopus homolog 1 (Drosophila)
E07 Hs.647774 NM_021205 RHOU Ras homolog gene family, member U
E08 Hs.401388 NM_021627 SENP2 SUMO1/sentrin/SMT3 specific peptidase 2
E09 Hs.713546 NM_003012 SFRP1 Secreted frizzled-related protein 1
E10 Hs.658169 NM_003014 SFRP4 Secreted frizzled-related protein 4
E11 Hs.500822 NM_022039 FBXW4 F-box and WD repeat domain containing 4
E12 Hs.728760 NM_004252 SLC9A3R1 Solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 1
F01 Hs.98367 NM_022454 SOX17 SRY (sex determining region Y)–box 17
F02 Hs.389457 NM_003181 T T, brachyury homolog (mouse)
F03 Hs.573153 NM_003202 TCF7 Transcription factor 7 (T cell specific, HMG box)
F04 Hs.516297 NM_031283 TCF7L1 Transcription factor 7–like 1 (T cell–specific, HMG box)
F05 Hs.197320 NM_005077 TLE1 Transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila)
F06 Hs.332173 NM_003260 TLE2 Transducin-like enhancer of split 2 (E(sp1) homolog, Drosophila)
F07 Hs.284122 NM_007191 WIF1 WNT inhibitory factor 1
F08 Hs.492974 NM_003882 WISP1 WNT1 inducible signaling pathway protein 1
F09 Hs.248164 NM_005430 WNT1 Wingless-type MMTV integration site family, member 1
F10 Hs.121540 NM_025216 WNT10A Wingless-type MMTV integration site family, member 10A
F11 Hs.108219 NM_004626 WNT11 Wingless-type MMTV integration site family, member 11
F12 Hs.272375 NM_057168 WNT16 Wingless-type MMTV integration site family, member 16
G01 Hs.567356 NM_003391 WNT2 Wingless-type MMTV integration site family member 2
G02 Hs.258575 NM_004185 WNT2B Wingless-type MMTV integration site family, member 2B
G03 Hs.445884 NM_030753 WNT3 Wingless-type MMTV integration site family, member 3
G04 Hs.336930 NM_033131 WNT3A Wingless-type MMTV integration site family, member 3A
G05 Hs.25766 NM_030761 WNT4 Wingless-type MMTV integration site family, member 4
G06 Hs.696364 NM_003392 WNT5A Wingless-type MMTV integration site family, member 5A
G07 Hs.306051 NM_032642 WNT5B Wingless-type MMTV integration site family, member 5B
G08 Hs.29764 NM_006522 WNT6 Wingless-type MMTV integration site family, member 6
G09 Hs.72290 NM_004625 WNT7A Wingless-type MMTV integration site family, member 7A
G10 Hs.512714 NM_058238 WNT7B Wingless-type MMTV integration site family, member 7B
G11 Hs.591274 NM_058244 WNT8A Wingless-type MMTV integration site family, member 8A
G12 Hs.149504 NM_003395 WNT9A Wingless-type MMTV integration site family, member 9A
H01 Hs.534255 NM_004048 B2M β-2-microglobulin
H02 Hs.412707 NM_000194 HPRT1 Hypoxanthine phosphoribosyltransferase 1
H03 Hs.728776 NM_012423 RPL13A Ribosomal protein L13a
H04 Hs.592355 NM_002046 GAPDH Glyceraldehyde-3-phosphate dehydrogenase
H05 Hs.520640 NM_001101 ACTB Actin, β
H06 N/A SA_00105 HGDC Human genomic DNA contamination
H07 N/A SA_00104 RTC RT control
H08 N/A SA_00104 RTC RT control
H09 N/A SA_00104 RTC RT control
H10 N/A SA_00103 PPC Positive PCR control
H11 N/A SA_00103 PPC Positive PCR control
H12 N/A SA_00103 PPC Positive PCR control
Table W2b. Average Ct.
Average Ct SD
Control Group Group 1 Control Group Group 1
A01 AES 24.35 24.48 0.645497 0.320156
A02 APC 30.4 30.45 0.774597 0.911043
A03 AXIN1 25.43 26.28 0.464579 0.330404
A04 BCL9 26.88 27.38 0.780491 0.512348
A05 BTRC 26.88 26.43 0.727438 0.670199
A06 FZD5 23.85 23.65 0.675771 0.6245
A07 CCND1 24.98 25.4 0.556028 0.804156
A08 CCND2 34.88 34.25 0.25 0.818535
A09 CCND3 28.4 28.7 0.316228 0.547723
A10 CSNK1A1 23.7 23.38 1.089342 0.434933
A11 CSNK1D 23.15 23.35 0.718795 0.173205
A12 CSNK1G1 31.23 31.2 0.377492 0.812404
B01 CSNK2A1 23.65 23.85 0.443471 0.310913
B02 CTBP1 22.7 23.08 0.522813 0.457347
B03 CTBP2 28.75 28.88 0.932738 1.212092
B04 CTNNB1 22.13 22.28 0.639661 0.492443
B05 CTNNBIP1 27.58 28.53 1.212092 0.623832
B06 CXXC4 32.38 30.9 1.078193 0.616441
B07 DAAM1 25.45 25.93 1.008299 0.655108
B08 DIXDC1 27.03 27.48 0.644851 0.670199
B09 DKK1 20.75 21.65 0.81035 1.567376
B10 DVL1 24.9 24.75 0.571548 0.5
B11 DVL2 29.33 29.1 0.411299 0.469042
B12 EP300 24.95 24.9 0.925563 0.739369
C01 FBXW11 25.93 25.95 0.579511 0.288675
C02 FBXW2 28.7 28.8 0.503322 0.707107
C03 FGF4 35 35 0 0
C04 FOSL1 29.25 29.25 0.404145 0.412311
C05 FOXN1 33.7 34.78 1.536229 0.45
C06 FRAT1 28.75 28.65 0.785281 0.723418
C07 FRZB 28.13 31.2 1.007886 4.436215
C08 FSHB 34.93 35 0.15 0
C09 FZD1 30.3 30.1 0.909212 1.042433
C10 FZD2 35 35 0 0
C11 FZD3 27.48 27.53 0.85 0.221736
C12 FZD4 26.73 27.5 0.780491 0.983192
D01 FZD6 25.23 25.13 0.607591 0.442531
D02 FZD7 27.38 27.3 0.639661 0.469042
D03 FZD8 33.15 33.5 0.714143 0.57735
D04 GSK3A 25.78 26.08 0.464579 0.298608
D05 GSK3B 23.6 23.6 0.716473 0.559762
D06 JUN 26.4 26.35 0.752773 0.704746
D07 KREMEN1 28.73 28.1 0.531507 0.216025
D08 LEF1 25.23 25.43 0.499166 0.680074
D09 LRP5 25.68 25.93 0.330404 0.262996
D10 LRP6 24.75 24.68 0.750555 0.567891
D11 MYC 25.33 25.73 0.629153 0.30957
D12 NKD1 23.8 23.7 0.326599 0.469042
Table W2b. (continued )
Average Ct SD
Control Group Group 1 Control Group Group 1
E01 NLK 26.3 26.2 0.668331 0.588784
E02 PITX2 28.1 27.83 0.983192 0.780491
E03 PORCN 27.9 28.18 0.559762 0.320156
E04 PPP2CA 26.7 26.83 0.432049 0.531507
E05 PPP2R1A 22.23 22.48 0.411299 0.320156
E06 PYGO1 28 28 0.535413 0.374166
E07 RHOU 23.78 24.18 0.537742 0.377492
E08 SENP2 25.2 25.48 0.496655 0.4272
E09 SFRP1 34.7 35 0.6 0
E10 SFRP4 29.83 30.58 0.914239 0.618466
E11 FBXW4 25.85 25.83 0.704746 0.585235
E12 SLC9A3R1 21.15 21.43 0.420317 0.35
F01 SOX17 35 35 0 0
F02 T 33.4 33.45 1.202775 0.619139
F03 TCF7 30.5 30.73 0.535413 0.377492
F04 TCF7L1 29.33 28.83 0.846069 0.287228
F05 TLE1 24.95 24.8 0.544671 0.648074
F06 TLE2 34.68 34.9 0.65 0.2
F07 WIF1 34.6 35 0.8 0
F08 WISP1 35 35 0 0
F09 WNT1 34.43 35 1.15 0
F10 WNT10A 32.65 33.53 2.977135 1.839157
F11 WNT11 30.58 32.03 0.411299 2.075853
F12 WNT16 34.2 33.75 1.28841 1.452584
G01 WNT2 35 35 0 0
G02 WNT2B 30.68 30.68 0.899537 1.652019
G03 WNT3 27.23 27.45 0.75 0.479583
G04 WNT3A 35 35 0 0
G05 WNT4 32.85 33.73 1.3 0.895824
G06 WNT5A 29.13 29.43 0.809835 0.537742
G07 WNT5B 34.73 35 0.377492 0
G08 WNT6 35 34.83 0 0.35
G09 WNT7A 35 35 0 0
G10 WNT7B 35 35 0 0
G11 WNT8A 35 34.95 0 0.1
G12 WNT9A 35 35 0 0
H01 B2M 21.05 21.55 0.519615 0.404145
H02 HPRT1 24.35 24.7 0.550757 0.637704
H03 RPL13A 19.73 19.55 0.55 0.369685
H04 GAPDH 16.58 16.65 0.660177 0.532291
H05 ACTB 19.13 18.95 0.655108 0.568624
H06 HGDC 35 35 0 0
H07 RTC 21.93 22.83 0.359398 0.330404
H08 RTC 22.43 23.4 0.368556 0.294392
H09 RTC 22.15 23.08 0.387298 0.499166
H10 PPC 18.65 19.23 0.493288 0.298608
H11 PPC 18.58 19.08 0.457347 0.330404
H12 PPC 18.3 18.78 0.391578 0.262996
Table W2c. Average ΔCt.
Average ΔC t [Ct (GOI) −
Average Ct (HKG)]
SD
Control Group Group 1 Control Group Group 1
A01 AES 4.383333 4.458333 0.551429 0.464579
A02 APC 10.433333 10.433333 0.438009 0.514242
A03 AXIN1 5.458333 6.258333 0.574376 0.512348
A04 BCL9 6.908333 7.358333 0.448351 0.403113
A05 BTRC 6.908333 6.408333 0.593405 0.481029
A06 FZD5 3.883333 3.633333 0.475706 0.316228
A07 CCND1 5.008333 5.383333 0.242479 0.404145
A08 CCND2 14.908333 14.233333 0.460575 0.684755
A09 CCND3 8.433333 8.683333 0.222777 0.31798
A10 CSNK1A1 3.733333 3.358333 0.833111 0.485627
A11 CSNK1D 3.183333 3.333333 0.439275 0.253859
A12 CSNK1G1 11.258333 11.183333 0.260164 0.420317
B01 CSNK2A1 3.683333 3.833333 0.244192 0.124722
B02 CTBP1 2.733333 3.058333 0.479197 0.514512
B03 CTBP2 8.783333 8.858333 0.684484 0.899537
B04 CTNNB1 2.158333 2.258333 0.341429 0.452462
B05 CTNNBIP1 7.608333 8.508333 1.0847 0.594652
B06 CXXC4 12.408333 10.883333 0.869813 0.738617
B07 DAAM1 5.483333 5.908333 0.654613 0.262996
B08 DIXDC1 7.058333 7.458333 0.412198 0.492443
B09 DKK1 0.783333 1.633333 0.630403 1.61314
B10 DVL1 4.933333 4.733333 0.448041 0.221108
B11 DVL2 9.358333 9.083333 0.21322 0.088192
B12 EP300 4.983333 4.883333 0.684484 0.574456
C01 FBXW11 5.958333 5.933333 0.490936 0.226078
C02 FBXW2 8.733333 8.783333 0.136083 0.440959
C03 FGF4 15.033333 14.983333 0.372181 0.412311
C04 FOSL1 9.283333 9.233333 0.19341 0.377124
C05 FOXN1 13.733333 14.758333 1.243948 0.471699
C06 FRAT1 8.783333 8.633333 0.664719 0.694422
C07 FRZB 8.158333 11.183333 0.678983 4.205948
C08 FSHB 14.958333 14.983333 0.409494 0.412311
C09 FZD1 10.333333 10.083333 0.822372 1.173314
C10 FZD2 15.033333 14.983333 0.372181 0.412311
C11 FZD3 7.508333 7.508333 0.578232 0.432371
C12 FZD4 6.758333 7.483333 0.525903 0.635085
D01 FZD6 5.258333 5.108333 0.438326 0.313138
D02 FZD7 7.408333 7.283333 0.56462 0.552771
D03 FZD8 13.183333 13.483333 1.027222 0.724952
D04 GSK3A 5.808333 6.058333 0.247019 0.287228
D05 GSK3B 3.633333 3.583333 0.445554 0.218581
D06 JUN 6.433333 6.333333 0.476873 0.454606
D07 KREMEN1 8.758333 8.083333 0.344668 0.338296
D08 LEF1 5.258333 5.408333 0.27672 0.718215
D09 LRP5 5.708333 5.908333 0.172938 0.195078
D10 LRP6 4.783333 4.658333 0.482662 0.211476
D11 MYC 5.358333 5.708333 0.568543 0.413991
D12 NKD1 3.833333 3.683333 0.306715 0.247207
Table W2c. (continued )
Average ΔC t [Ct (GOI) −
Average Ct (HKG)]
SD
Control Group Group 1 Control Group Group 1
E01 NLK 6.333333 6.183333 0.52985 0.422953
E02 PITX2 8.133333 7.808333 0.894841 0.822091
E03 PORCN 7.933333 8.158333 0.552436 0.330404
E04 PPP2CA 6.733333 6.808333 0.098131 0.183333
E05 PPP2R1A 2.258333 2.458333 0.303529 0.397562
E06 PYGO1 8.033333 7.983333 0.306715 0.310913
E07 RHOU 3.808333 4.158333 0.378472 0.183333
E08 SENP2 5.233333 5.458333 0.476873 0.254406
E09 SFRP1 14.733333 14.983333 0.313877 0.412311
E10 SFRP4 9.858333 10.558333 0.655673 0.206155
E11 FBXW4 5.883333 5.808333 0.599691 0.476387
E12 SLC9A3R1 1.183333 1.408333 0.270117 0.294863
F01 SOX17 15.033333 14.983333 0.372181 0.412311
F02 T 13.433333 13.433333 0.855483 0.507718
F03 TCF7 10.533333 10.708333 0.320878 0.705731
F04 TCF7L1 9.358333 8.808333 0.572438 0.236291
F05 TLE1 4.983333 4.783333 0.345875 0.425572
F06 TLE2 14.708333 14.883333 0.357331 0.378594
F07 WIF1 14.633333 14.983333 0.495162 0.412311
F08 WISP1 15.033333 14.983333 0.372181 0.412311
F09 WNT1 14.458333 14.983333 0.833278 0.412311
F10 WNT10A 12.683333 13.508333 2.646941 1.631717
F11 WNT11 10.608333 12.008333 0.395694 1.678044
F12 WNT16 14.233333 13.733333 1.015801 1.244544
G01 WNT2 15.033333 14.983333 0.372181 0.412311
G02 WNT2B 10.708333 10.658333 0.699934 1.279865
G03 WNT3 7.258333 7.433333 0.606371 0.418994
G04 WNT3A 15.033333 14.983333 0.372181 0.412311
G05 WNT4 12.883333 13.708333 1.143905 0.820738
G06 WNT5A 9.158333 9.408333 0.554694 0.305959
G07 WNT5B 14.758333 14.983333 0.707827 0.412311
G08 WNT6 15.033333 14.808333 0.372181 0.419325
G09 WNT7A 15.033333 14.983333 0.372181 0.412311
G10 WNT7B 15.033333 14.983333 0.372181 0.412311
G11 WNT8A 15.033333 14.933333 0.372181 0.394405
G12 WNT9A 15.033333 14.983333 0.372181 0.412311
H01 B2M 1.083333 1.533333 0.402308 0.169967
H02 HPRT1 4.383333 4.683333 0.361581 0.51099
H03 RPL13A −0.241667 −0.466667 0.242479 0.235702
H04 GAPDH −3.391667 −3.366667 0.29234 0.323179
H05 ACTB −0.841667 −1.066667 0.604535 0.169967
H06 HGDC 15.033333 14.983333 0.372181 0.412311
H07 RTC 1.958333 2.808333 0.602695 0.56001
H08 RTC 2.458333 3.383333 0.598996 0.465475
H09 RTC 2.183333 3.058333 0.586578 0.700991
H10 PPC −1.316667 −0.791667 0.355382 0.471699
H11 PPC −1.391667 −0.941667 0.21322 0.533594
H12 PPC −1.666667 −1.241667 0.237268 0.485627
Table W2d. 2−Average(ΔCt).
2−Average(ΔCt)
Control Group Group 1
A01 AES 0.047917 0.045489
A02 APC 0.000723 0.000723
A03 AXIN1 0.022745 0.013063
A04 BCL9 0.008325 0.006094
A05 BTRC 0.008325 0.011773
A06 FZD5 0.067764 0.080586
A07 CCND1 0.03107 0.023958
A08 CCND2 0.000033 0.000052
A09 CCND3 0.002893 0.002433
A10 CSNK1A1 0.075189 0.097508
A11 CSNK1D 0.110083 0.099213
A12 CSNK1G1 0.000408 0.00043
B01 CSNK2A1 0.077841 0.070154
B02 CTBP1 0.150378 0.120047
B03 CTBP2 0.00227 0.002155
B04 CTNNB1 0.224015 0.209013
B05 CTNNBIP1 0.005125 0.002746
B06 CXXC4 0.000184 0.000529
B07 DAAM1 0.022354 0.01665
B08 DIXDC1 0.007503 0.005686
B09 DKK1 0.581023 0.322343
B10 DVL1 0.032728 0.037595
B11 DVL2 0.001524 0.001844
B12 EP300 0.031613 0.033882
C01 FBXW11 0.016083 0.016364
C02 FBXW2 0.00235 0.00227
C03 FGF4 0.00003 0.000031
C04 FOSL1 0.001605 0.001661
C05 FOXN1 0.000073 0.000036
C06 FRAT1 0.00227 0.002518
C07 FRZB 0.0035 0.00043
C08 FSHB 0.000031 0.000031
C09 FZD1 0.000775 0.000922
C10 FZD2 0.00003 0.000031
C11 FZD3 0.005492 0.005492
C12 FZD4 0.009237 0.005588
D01 FZD6 0.026127 0.028989
D02 FZD7 0.005887 0.006419
D03 FZD8 0.000108 0.000087
D04 GSK3A 0.017845 0.015006
D05 GSK3B 0.080586 0.083427
D06 JUN 0.011571 0.012402
D07 KREMEN1 0.002309 0.003687
D08 LEF1 0.026127 0.023547
D09 LRP5 0.019126 0.01665
D10 LRP6 0.036314 0.039601
D11 MYC 0.024377 0.019126
D12 NKD1 0.070154 0.077841
Table W2d. (continued )
2−Average(ΔCt)
Control Group Group 1
E01 NLK 0.012402 0.01376
E02 PITX2 0.003561 0.004461
E03 PORCN 0.004091 0.0035
E04 PPP2CA 0.009399 0.008923
E05 PPP2R1A 0.209013 0.181957
E06 PYGO1 0.003817 0.003952
E07 RHOU 0.07138 0.056004
E08 SENP2 0.026583 0.022745
E09 SFRP1 0.000037 0.000031
E10 SFRP4 0.001077 0.000663
E11 FBXW4 0.016941 0.017845
E12 SLC9A3R1 0.440333 0.376747
F01 SOX17 0.00003 0.000031
F02 T 0.00009 0.00009
F03 TCF7 0.000675 0.000598
F04 TCF7L1 0.001524 0.002231
F05 TLE1 0.031613 0.036314
F06 TLE2 0.000037 0.000033
F07 WIF1 0.000039 0.000031
F08 WISP1 0.00003 0.000031
F09 WNT1 0.000044 0.000031
F10 WNT10A 0.000152 0.000086
F11 WNT11 0.000641 0.000243
F12 WNT16 0.000052 0.000073
G01 WNT2 0.00003 0.000031
G02 WNT2B 0.000598 0.000619
G03 WNT3 0.006532 0.005786
G04 WNT3A 0.00003 0.000031
G05 WNT4 0.000132 0.000075
G06 WNT5A 0.00175 0.001472
G07 WNT5B 0.000036 0.000031
G08 WNT6 0.00003 0.000035
G09 WNT7A 0.00003 0.000031
G10 WNT7B 0.00003 0.000031
G11 WNT8A 0.00003 0.000032
G12 WNT9A 0.00003 0.000031
H01 B2M 0.471937 0.345478
H02 HPRT1 0.047917 0.03892
H03 RPL13A 1.182358 1.381913
H04 GAPDH 10.495265 10.314962
H05 ACTB 1.792119 2.094588
H06 HGDC 0.00003 0.000031
H07 RTC 0.257326 0.14276
H08 RTC 0.181957 0.095833
H09 RTC 0.220166 0.120047
H10 PPC 2.490899 1.731073
H11 PPC 2.623816 1.920746
H12 PPC 3.174802 2.364716
Table W2e. Fold Change.
Fold Change (Compared to Control Group)
Group 1
Fold Change 95% CI Comments
A01 AES 0.9493 (0.48, 1.41) Okay
A02 APC 1 (0.54, 1.46) B
A03 AXIN1 0.5743 (0.27, 0.87) Okay
A04 BCL9 0.732 (0.43, 1.03) Okay
A05 BTRC 1.4142 (0.68, 2.15) Okay
A06 FZD5 1.1892 (0.73, 1.65) Okay
A07 CCND1 0.7711 (0.52, 1.02) Okay
A08 CCND2 1.5966 (0.70, 2.49) B
A09 CCND3 0.8409 (0.62, 1.06) Okay
A10 CSNK1A1 1.2968 (0.45, 2.15) Okay
A11 CSNK1D 0.9013 (0.59, 1.21) Okay
A12 CSNK1G1 1.0534 (0.70, 1.41) B
B01 CSNK2A1 0.9013 (0.73, 1.07) Okay
B02 CTBP1 0.7983 (0.42, 1.18) Okay
B03 CTBP2 0.9493 (0.22, 1.68) Okay
B04 CTNNB1 0.933 (0.57, 1.29) Okay
B05 CTNNBIP1 0.5359 (0.09, 0.99) Okay
B06 CXXC4 2.8779 (0.65, 5.11) Okay
B07 DAAM1 0.7448 (0.39, 1.10) Okay
B08 DIXDC1 0.7579 (0.43, 1.09) Okay
B09 DKK1 0.5548 (0.00001, 1.21) Okay
B10 DVL1 1.1487 (0.76, 1.54) Okay
B11 DVL2 1.21 (1.02, 1.40) Okay
B12 EP300 1.0718 (0.42, 1.72) Okay
C01 FBXW11 1.0175 (0.64, 1.39) Okay
C02 FBXW2 0.9659 (0.66, 1.27) Okay
C03 FGF4 1.0353 (0.64, 1.43) C
C04 FOSL1 1.0353 (0.74, 1.33) Okay
C05 FOXN1 0.4914 (0.05, 0.94) B
C06 FRAT1 1.1096 (0.39, 1.83) Okay
C07 FRZB 0.1229 (0.00001, 0.48) A
C08 FSHB 0.9828 (0.59, 1.37) B
C09 FZD1 1.1892 (0.03, 2.35) B
C10 FZD2 1.0353 (0.64, 1.43) C
C11 FZD3 1 (0.51, 1.49) Okay
C12 FZD4 0.605 (0.27, 0.94) Okay
D01 FZD6 1.1096 (0.70, 1.52) Okay
D02 FZD7 1.0905 (0.51, 1.68) Okay
D03 FZD8 0.8123 (0.12, 1.51) B
D04 GSK3A 0.8409 (0.62, 1.06) Okay
D05 GSK3B 1.0353 (0.69, 1.38) Okay
D06 JUN 1.0718 (0.59, 1.55) Okay
D07 KREMEN1 1.5966 (1.07, 2.12) Okay
D08 LEF1 0.9013 (0.43, 1.37) Okay
D09 LRP5 0.8706 (0.72, 1.02) Okay
D10 LRP6 1.0905 (0.70, 1.48) Okay
D11 MYC 0.7846 (0.41, 1.16) Okay
D12 NKD1 1.1096 (0.81, 1.41) Okay
E01 NLK 1.1096 (0.60, 1.62) Okay
E02 PITX2 1.2527 (0.22, 2.29) Okay
E03 PORCN 0.8556 (0.48, 1.23) Okay
E04 PPP2CA 0.9493 (0.82, 1.08) Okay
E05 PPP2R1A 0.8706 (0.57, 1.17) Okay
E06 PYGO1 1.0353 (0.73, 1.34) Okay
E07 RHOU 0.7846 (0.56, 1.01) Okay
E08 SENP2 0.8556 (0.54, 1.17) Okay
E09 SFRP1 0.8409 (0.54, 1.14) B
E10 SFRP4 0.6156 (0.33, 0.90) A
E11 FBXW4 1.0534 (0.51, 1.60) Okay
E12 SLC9A3R1 0.8556 (0.62, 1.09) Okay
F01 SOX17 1.0353 (0.64, 1.43) C
Table W2e. (continued )
Fold Change (Compared to Control Group)
Group 1
Fold Change 95% CI Comments
F02 T 1 (0.32, 1.68) B
F03 TCF7 0.8858 (0.42, 1.35) B
F04 TCF7L1 1.4641 (0.85, 2.08) Okay
F05 TLE1 1.1487 (0.72, 1.58) Okay
F06 TLE2 0.8858 (0.57, 1.20) B
F07 WIF1 0.7846 (0.44, 1.13) B
F08 WISP1 1.0353 (0.64, 1.43) C
F09 WNT1 0.695 (0.26, 1.13) B
F10 WNT10A 0.5645 (0.00001, 1.76) B
F11 WNT11 0.3789 (0.00001, 0.82) B
F12 WNT16 1.4142 (0.00001, 2.96) B
G01 WNT2 1.0353 (0.64, 1.43) C
G02 WNT2B 1.0353 (0.01, 2.06) B
G03 WNT3 0.8858 (0.44, 1.33) Okay
G04 WNT3A 1.0353 (0.64, 1.43) C
G05 WNT4 0.5645 (0.02, 1.10) B
G06 WNT5A 0.8409 (0.48, 1.20) Okay
G07 WNT5B 0.8556 (0.38, 1.33) B
G08 WNT6 1.1688 (0.72, 1.61) B
G09 WNT7A 1.0353 (0.64, 1.43) C
G10 WNT7B 1.0353 (0.64, 1.43) C
G11 WNT8A 1.0718 (0.68, 1.47) B
G12 WNT9A 1.0353 (0.64, 1.43) C
H01 B2M 0.732 (0.51, 0.95) Okay
H02 HPRT1 0.8123 (0.47, 1.16) Okay
H03 RPL13A 1.1688 (0.90, 1.44) Okay
H04 GAPDH 0.9828 (0.69, 1.27) Okay
H05 ACTB 1.1688 (0.67, 1.67) Okay
H06 HGDC 1.0353 (0.64, 1.43) C
H07 RTC 0.5548 (0.24, 0.86) Okay
H08 RTC 0.5267 (0.26, 0.80) Okay
H09 RTC 0.5453 (0.21, 0.88) Okay
H10 PPC 0.695 (0.42, 0.97) Okay
H11 PPC 0.732 (0.45, 1.02) Okay
H12 PPC 0.7448 (0.47, 1.02) Okay
Comments:
A: This gene’s average threshold cycle is relatively high (>30) in either the control or the test
sample and is reasonably low in the other sample (<30).
These data mean that the gene’s expression is relatively low in one sample and reasonably detected
in the other sample, suggesting that the actual fold-change value is at least as large as the calculated
and reported fold-change result.
This fold-change result may also have greater variations if P > .05; therefore, it is important to have
a sufficient number of biologic replicates to validate the result for this gene.
B: This gene’s average threshold cycle is relatively high (>30), meaning that its relative expression
level is low, in both control and test samples, and the P value for the fold change is either un-
available or relatively high (P > .05).
This fold-change result may also have greater variations; therefore, it is important to have a suf-
ficient number of biologic replicates to validate the result for this gene.
C: This gene’s average threshold cycle is either not determined or greater than the defined cutoff
value (default 35), in both samples meaning that its expression was undetected, making this fold-
change result erroneous and uninterpretable.
Fold change and fold regulation:
Fold change (2−ΔΔCt) is the normalized gene expression (2−ΔCt) in the test sample divided by the
normalized gene expression (2−ΔCt) in the control sample.
Fold regulation represents fold-change results in a biologically meaningful way. Fold-change values
greater than 1 indicate a positive or an up-regulation, and the fold regulation is equal to the fold change.
Fold-change values less than 1 indicate a negative or down-regulation, and the fold regulation is the
negative inverse of the fold change.
Fold-change and fold-regulation values greater than 2 are indicated in red; fold-change values less
than 0.5 and fold-regulation values less than −2 are indicated in blue.
Table W2f. P values.
P Value (Compared to Control Group)
Group 1
A01 AES 0.792341
A02 APC 0.965095
A03 AXIN1 0.125466
A04 BCL9 0.200823
A05 BTRC 0.198872
A06 FZD5 0.434184
A07 CCND1 0.1434
A08 CCND2 0.130908
A09 CCND3 0.26405
A10 CSNK1A1 0.581515
A11 CSNK1D 0.502102
A12 CSNK1G1 0.690156
B01 CSNK2A1 0.294784
B02 CTBP1 0.379823
B03 CTBP2 0.96217
B04 CTNNB1 0.757378
B05 CTNNBIP1 0.138199
B06 CXXC4 0.043045
B07 DAAM1 0.294942
B08 DIXDC1 0.291973
B09 DKK1 0.746279
B10 DVL1 0.490117
B11 DVL2 0.042473
B12 EP300 0.888903
C01 FBXW11 0.941277
C02 FBXW2 0.995686
C03 FGF4 0.836286
C04 FOSL1 0.714447
C05 FOXN1 0.156795
C06 FRAT1 0.689437
C07 FRZB 0.76046
C08 FSHB 0.954679
C09 FZD1 0.515336
C10 FZD2 0.836286
C11 FZD3 0.922969
C12 FZD4 0.135681
D01 FZD6 0.652247
D02 FZD7 0.769613
D03 FZD8 0.548591
D04 GSK3A 0.225384
D05 GSK3B 0.967886
D06 JUN 0.790172
D07 KREMEN1 0.033755
D08 LEF1 0.90179
D09 LRP5 0.181439
D10 LRP6 0.780073
D11 MYC 0.292486
D12 NKD1 0.506295
E01 NLK 0.693875
E02 PITX2 0.718265
Table W2f. (continued )
P Value (Compared to Control Group)
Group 1
E03 PORCN 0.416707
E04 PPP2CA 0.535224
E05 PPP2R1A 0.475922
E06 PYGO1 0.833288
E07 RHOU 0.114162
E08 SENP2 0.356227
E09 SFRP1 0.441863
E10 SFRP4 0.119764
E11 FBXW4 0.886316
E12 SLC9A3R1 0.288113
F01 SOX17 0.836286
F02 T 0.836247
F03 TCF7 0.879469
F04 TCF7L1 0.126211
F05 TLE1 0.461623
F06 TLE2 0.558308
F07 WIF1 0.357022
F08 WISP1 0.836286
F09 WNT1 0.333883
F10 WNT10A 0.398512
F11 WNT11 0.104759
F12 WNT16 0.495047
G01 WNT2 0.836286
G02 WNT2B 0.690109
G03 WNT3 0.545446
G04 WNT3A 0.836286
G05 WNT4 0.151461
G06 WNT5A 0.380818
G07 WNT5B 0.526959
G08 WNT6 0.428128
G09 WNT7A 0.836286
G10 WNT7B 0.836286
G11 WNT8A 0.713394
G12 WNT9A 0.836286
H01 B2M 0.07127
H02 HPRT1 0.439236
H03 RPL13A 0.214986
H04 GAPDH 0.937356
H05 ACTB 0.727042
H06 HGDC 0.836286
H07 RTC 0.102875
H08 RTC 0.089411
H09 RTC 0.115337
H10 PPC 0.124293
H11 PPC 0.171647
H12 PPC 0.184196
P value:
The P values are calculated based on a Student’s t test of the replicate 2−ΔCt values for each gene in
the control group and treatment groups, and P values less than .05 are indicated in red.
Table W2g. Fold Regulation.
Up-regulation/Down-regulation
(Compared to Control Group)
Group 1
Fold Regulation Comments
A01 AES −1.0534 Okay
A02 APC 1 B
A03 AXIN1 −1.7411 Okay
A04 BCL9 −1.366 Okay
A05 BTRC 1.4142 Okay
A06 FZD5 1.1892 Okay
A07 CCND1 −1.2968 Okay
A08 CCND2 1.5966 B
A09 CCND3 −1.1892 Okay
A10 CSNK1A1 1.2968 Okay
A11 CSNK1D −1.1096 Okay
A12 CSNK1G1 1.0534 B
B01 CSNK2A1 −1.1096 Okay
B02 CTBP1 −1.2527 Okay
B03 CTBP2 −1.0534 Okay
B04 CTNNB1 −1.0718 Okay
B05 CTNNBIP1 −1.8661 Okay
B06 CXXC4 2.8779 Okay
B07 DAAM1 −1.3426 Okay
B08 DIXDC1 −1.3195 Okay
B09 DKK1 −1.8025 Okay
B10 DVL1 1.1487 Okay
B11 DVL2 1.21 Okay
B12 EP300 1.0718 Okay
C01 FBXW11 1.0175 Okay
C02 FBXW2 −1.0353 Okay
C03 FGF4 1.0353 C
C04 FOSL1 1.0353 Okay
C05 FOXN1 −2.035 B
C06 FRAT1 1.1096 Okay
C07 FRZB −8.1398 A
C08 FSHB −1.0175 B
C09 FZD1 1.1892 B
C10 FZD2 1.0353 C
C11 FZD3 1 Okay
C12 FZD4 −1.6529 Okay
D01 FZD6 1.1096 Okay
D02 FZD7 1.0905 Okay
D03 FZD8 −1.2311 B
D04 GSK3A −1.1892 Okay
D05 GSK3B 1.0353 Okay
D06 JUN 1.0718 Okay
D07 KREMEN1 1.5966 Okay
D08 LEF1 −1.1096 Okay
D09 LRP5 −1.1487 Okay
D10 LRP6 1.0905 Okay
D11 MYC −1.2746 Okay
D12 NKD1 1.1096 Okay
E01 NLK 1.1096 Okay
E02 PITX2 1.2527 Okay
E03 PORCN −1.1688 Okay
E04 PPP2CA −1.0534 Okay
E05 PPP2R1A −1.1487 Okay
E06 PYGO1 1.0353 Okay
E07 RHOU −1.2746 Okay
E08 SENP2 −1.1688 Okay
E09 SFRP1 −1.1892 B
E10 SFRP4 −1.6245 A
E11 FBXW4 1.0534 Okay
E12 SLC9A3R1 −1.1688 Okay
F01 SOX17 1.0353 C
Table W2g. (continued )
Up-regulation/Down-regulation
(Compared to Control Group)
Group 1
Fold Regulation Comments
F02 T 1 B
F03 TCF7 −1.129 B
F04 TCF7L1 1.4641 Okay
F05 TLE1 1.1487 Okay
F06 TLE2 −1.129 B
F07 WIF1 −1.2746 B
F08 WISP1 1.0353 C
F09 WNT1 −1.4389 B
F10 WNT10A −1.7715 B
F11 WNT11 −2.639 B
F12 WNT16 1.4142 B
G01 WNT2 1.0353 C
G02 WNT2B 1.0353 B
G03 WNT3 −1.129 Okay
G04 WNT3A 1.0353 C
G05 WNT4 −1.7715 B
G06 WNT5A −1.1892 Okay
G07 WNT5B −1.1688 B
G08 WNT6 1.1688 B
G09 WNT7A 1.0353 C
G10 WNT7B 1.0353 C
G11 WNT8A 1.0718 B
G12 WNT9A 1.0353 C
H01 B2M −1.366 Okay
H02 HPRT1 −1.2311 Okay
H03 RPL13A 1.1688 Okay
H04 GAPDH −1.0175 Okay
H05 ACTB 1.1688 Okay
H06 HGDC 1.0353 C
H07 RTC −1.8025 Okay
H08 RTC −1.8987 Okay
H09 RTC −1.834 Okay
H10 PPC −1.4389 Okay
H11 PPC −1.366 Okay
H12 PPC −1.3426 Okay
Comments:
A: This gene’s average threshold cycle is relatively high (>30) in either the control or the test
sample and is reasonably low in the other sample (<30).
These data mean that the gene’s expression is relatively low in one sample and reasonably detected
in the other sample suggesting that the actual fold-change value is at least as large as the calculated
and reported fold-change result.
This fold-change result may also have greater variations if P > .05; therefore, it is important to have
a sufficient number of biologic replicates to validate the result for this gene.
B: This gene’s average threshold cycle is relatively high (>30), meaning that its relative expression
level is low, in both control and test samples, and the P value for the fold change is either un-
available or relatively high (P > .05).
This fold-change result may also have greater variations; therefore, it is important to have a suf-
ficient number of biologic replicates to validate the result for this gene.
C: This gene’s average threshold cycle is either not determined or greater than the defined cutoff
value (default 35), in both samples meaning that its expression was undetected, making this fold-
change result erroneous and uninterpretable.
Fold change and fold regulation:
Fold change (2−ΔΔCt) is the normalized gene expression (2−ΔCt) in the test sample divided by the
normalized gene expression (2−ΔCt) in the control sample.
Fold regulation represents fold-change results in a biologically meaningful way. Fold-change values
greater than 1 indicate a positive or an up-regulation, and the fold regulation is equal to the fold change.
Fold-change values less than 1 indicate a negative or down-regulation, and the fold regulation is the
negative inverse of the fold change.
Fold-change and fold-regulation values greater than 2 are indicated in red; fold-change values less
than 0.5 and fold-regulation values less than −2 are indicated in blue.
Table W3. β-Catenin Mutational Status in Hepatoblastoma Specimens.
Sample Histology Mutational Status CITED1 Densitometry β-Catenin Densitometry
1 2 2 40.73 1.15
2 1 2 28.97 1.28
3 2 ND 27.79 0.61
4 2 ND 40.36 0.56
5 1 1 39.13 0.2
6 2 2 19.84 0.4
7 1 1 31.18 0.63
8 1 2 7.14 0.34
9 2 1 52.66 0.56
10 1 1 ND 1.77
11 1 ND 40.27 1.42
12 2 2 43.9 1.47
13 2 2 63.69 1.02
14 2 ND 47.42 1.29
15 1 1 9.78 0.28
16 1 2 42.78 1.7
17 2 2 40.82 1.58
18 2 2 18.07 ND
19 2 2 41.59 0.42
Histology 1, fetal; histology 2, EMEF; mutational status 1, wild type; mutational status 2, mutant;
ND, not determined.
Figure W1. Serial sections immunohistochemically stained for
β-catenin and CITED1 reveal expression in similar cell populations
(serial sections A and B: originalmagnification, ×200; serial sections
C and D: original magnification, ×400).
